000			07243namaa22004451i 4500
003			EG-GICUC
005			20251109100151.0
008			251109s2025 ua a|||frm||| 000 0 eng d
040			_aEG-GICUC _beng _cEG-GICUC _dEG-GICUC _erda
041	0		_aeng _beng _bara
049			_aDeposit
082	0	4	_a616.99449
092			_a616.99449 _221
097			_aM.Sc
099			_aCai01.12.21.M.Sc.2025.Am.E
100	0		_aAmira Hossny Awad Hassan Elbanna, _epreparation.
245	1	0	_aExpression pattern and clinical significance of EXT1 in breast cancer / _cby Amira Hossny Awad Hassan Elbanna ; Supervisors Prof. Dr. Sherif Abdelaziz Ibrahim, Prof. Dr. Ahmed Hassan Abd El-Raouf, Prof. Dr. Mahmoud Mohamed Kamel.
246	1	5	_aاﻟﻨﻤﻂ اﻟﺘﻌﺒﯿﺮي واﻷھﻤﯿﺔ اﻟﺴﺮﯾﺮﯾﺔ ل "أي اﻛﺲ ﺗﻲ ١ " ﻓﻲ ﺳﺮطﺎن اﻟﺜﺪي
264		0	_c2025.
300			_a99 pages : _billustrations ; _c25 cm. + _eCD.
336			_atext _2rda content
337			_aUnmediated _2rdamedia
338			_avolume _2rdacarrier
502			_aThesis (M.Sc)-Cairo University, 2025.
504			_aBibliography: pages 75-96.
520		3	_aBackground: Exostosin 1 (EXT1) encodes a type II transmembrane glycosyltransferase residing in the endoplasmic reticulum and plays an essential role in the elongation of heparan sulfate chain biosynthesis. Additionally, EXT1 may act as an oncogene, promoting cell proliferation and metastasis of cancer cells. Aim of study: to assess the expression pattern, prognostic value, and immunological implications of EXT1 in breast cancer. Materials and Methods: Immunohistochemical staining of EXT1 was evaluated in 85 breast cancer patients. Patients were categorized into molecular subtypes, such as luminal A, luminal B, human epidermal growth factor receptor 2 (HER2), and triple-negative breast cancer (TNBC). Correlations of EXT1 immunostaining with clinicopathological parameters, tumor immune infiltration, and immune cell surface markers assessed by TIMER were analyzed. Furthermore, survival analysis was conducted to reveal EXT1’s prognostic value. Results: EXT1 expression was significantly associated with estrogen receptor (ER) status, molecular sub-types, and recurrence status. Moreover, EXT1 expression was positively associated with poor overall survival (OS) and relapse-free survival (RFS). Immune infiltration analysis indicated that EXT1 expression was positively correlated with CD8+ T cells, CD4+ T cells, macrophages, neutrophils, and dendritic cells (DCs), although it showed a negative correlation with tumor purity. Conclusion: Overall, this study suggests that the elevated EXT1 expression, particularly in TNBC, is positively correlated with poor prognosis and with immune-infiltrated cells in breast cancer. Therefore, it may emerge as an independent prognostic biomarker, immunological marker, and a potential future therapeutic target for the most aggressive TNBC subtype.
520		3	_aاﻟﺨﻠﻔﯿﺔ: ﯾُﺸﻔّﺮ ﺟﯿﻦ اﻛﺴﻮﺳﺘﻮﺳﻦ 1) EXT1) ﻹﻧﺰﯾﻢ ﻏﻠﯿﻜﻮزﯾﻠﺘﺮاﻧﺴﻔﯿﺮاز ﻣﻦ اﻟﻨﻮع اﻟﺜﺎﻧﻲ اﻟﺬي ﯾﻘﺒﻊ ﻓﻲ اﻟﺸﺒﻜﺔ اﻹﻧﺪوﺑﻼزﻣﯿﺔ، وﯾﻠﻌﺐ دورً ا أﺳﺎﺳﯿًﺎ ﻓﻲ إطﺎﻟﺔ ﺳﻠﺴﻠﺔ ﺗﺨﻠﯿﻖ اﻟﮭﯿﺒﺎران ﺳﻠﻔﺎت. ﺑﺎﻹﺿﺎﻓﺔ إﻟﻰ ذﻟﻚ، ﻗﺪ ﯾﻌﻤﻞEXT1 ﻛﺠﯿﻦ ﻣﺴﺮطﻦ، ﻣﻤﺎ ﯾﻌﺰز ﺗﻜﺎﺛﺮ اﻟﺨﻼﯾﺎ واﻧﺘﻘﺎل اﻟﺨﻼﯾﺎ اﻟﺴﺮطﺎﻧﯿﺔ. ھﺪف اﻟﺪراﺳﺔ :ﻛﺎن اﻟﮭﺪف ﻣﻦ اﻟﺪراﺳﺔ ﺗﻘﯿﯿﻢ ﻧﻤﻂ اﻟﺘﻌﺒﯿﺮ واﻟﻘﯿﻤﺔ اﻟﺘﻨﺒﺆﯾﺔ واﻵﺛﺎر اﻟﻤﻨﺎﻋﯿﺔ ﻟـEXT1 ﻓﻲ ﺳﺮطﺎن اﻟﺜﺪي. اﻟﻤﻮاد واﻟﻄُﺮق :ﺗﻢ ﺗﻘﯿﯿﻢ ﺻﺒﻐﺔ اﻟﻤﻨﺎﻋﯿﺔ ﻟـEXT1 ﻓﻲ 85 ﻣﺮﯾﻀﺔ ﺑﺴﺮطﺎن اﻟﺜﺪي. ﺗﻢ ﺗﺼﻨﯿﻒ اﻟﻤﺮﺿﻰ إﻟﻰ اﻷﻧﻮاع اﻟﻔﺮﻋﯿﺔ اﻟﺠﺰﯾﺌﯿﺔ ﻣﺜﻞ ﻟﻮﻣﻨﺎلA ، ﻟﻮﻣﻨﺎلB ، ﻣﺴﺘﻘﺒﻼت ﻋﺎﻣﻞ اﻟﻨﻤﻮ اﻟﺒﺸﺮي HER2)2) ، وﺳﺮطﺎن اﻟﺜﺪي اﻟﺜﻼﺛﻲ اﻟﺴﻠﺒﻲ TNBC)(. ﺗﻢ ﺗﺤﻠﯿﻞ اﻟﻌﻼﻗﺎت ﺑﯿﻦ ﺻﺒﻐﺔ EXT1اﻟﻤﻨﺎﻋﯿﺔ واﻟﻤﻌﺎﯾﯿﺮ اﻹﻛﻠﯿﻨﯿﻜﯿﺔ اﻟﻤﺮﺿﯿﺔ، ﺗﺴﻠﻞ اﻟﻮرم اﻟﻤﻨﺎﻋﻲ، وﻋﻼﻣﺎت ﺳﻄﺢ اﻟﺨﻼﯾﺎ اﻟﻤﻨﺎﻋﯿﺔ اﻟﺘﻲ ﺗﻢ ﺗﻘﯿﯿﻤﮭﺎ ﺑﺎﺳﺘﺨﺪام ﻗﺎﻋﺪة ﺑﯿﺎﻧﺎت TIMER. ﻋﻼوة ﻋﻠﻰ ذﻟﻚ، ﺗﻢ إﺟﺮاء ﺗﺤﻠﯿﻞ ﻟﻠﺒﻘﺎء ﻟﻠﻜﺸﻒ ﻋﻦ اﻟﻘﯿﻤﺔ اﻟﺘﻨﺒﺆﯾﺔ ﻟـEXT1 . اﻟﻨﺘﺎﺋﺞ :ﻛﺎن ﺗﻌﺒﯿﺮ EXT1 ﻣﺮﺗﺒﻄًﺎ ﺑﺸﻜﻞ ﻛﺒﯿﺮ ﺑﺤﺎﻟﺔ ﻣﺴﺘﻘﺒﻼت اﻹﺳﺘﺮوﺟﯿﻦ ER)(، اﻷﻧﻮاع اﻟﻔﺮﻋﯿﺔ اﻟﺠﺰﯾﺌﯿﺔ، وﺣﺎﻟﺔ اﻟﺘﻜﺮار. ﺑﺎﻹﺿﺎﻓﺔ إﻟﻰ ذﻟﻚ، ﻛﺎن ﺗﻌﺒﯿﺮEXT1 ﻣﺮﺗﺒﻄًﺎ ﺑﺸﻜﻞ إﯾﺠﺎﺑﻲ ﺑﺴﻮء اﻟﺒﻘﺎء اﻟﻌﺎم OS)( واﻟﺒﻘﺎء اﻟﺨﺎﻟﻲ ﻣﻦ اﻻﻧﺘﻜﺎس RFS)(. أظﮭﺮ ﺗﺤﻠﯿﻞ ﺗﺴﻠﻞ اﻟﻤﻨﺎﻋﺔ أن ﺗﻌﺒﯿﺮ EXT1 ﻛﺎن ﻣﺮﺗﺒﻄًﺎ إﯾﺠﺎﺑﯿًﺎ ﻣﻊ ﺧﻼﯾﺎT اﻟﺴﺎﻣﺔCD8)+( ، ﺧﻼﯾﺎT اﻟﻤﺴﺎﻋﺪة( CD4)+ ، اﻟﺒﻼﻋﻢ، اﻟﺨﻼﯾﺎ اﻟﻤﺘﻌﺎدﻟﺔ، واﻟﺨﻼﯾﺎ اﻟﻤﺘﻐﺼﻨﺔ(DCs) ، ﻋﻠﻰ اﻟﺮﻏﻢ ﻣﻦ أﻧﮫ أظﮭﺮ ارﺗﺒﺎطًﺎ ﺳﻠﺒﯿًﺎ ﻣﻊ ﻧﻘﺎء اﻟﻮرم. اﻟﺨﻼﺻﺔ: ﺑﺸﻜﻞ ﻋﺎم، ﺗﺸﯿﺮ ھﺬه اﻟﺪراﺳﺔ إﻟﻰ أن ارﺗﻔﺎع ﺗﻌﺒﯿﺮEXT1 ، ﺧﺎﺻﺔ ﻓﻲ ﻧﻮعTNBC ، ﻣﺮﺗﺒﻂ ﺑﺸﻜﻞ إﯾﺠﺎﺑﻲ ﺑﺴﻮء اﻟﺘﻨﺒﺆ وﺑﺘﺴﻠﻞ اﻟﺨﻼﯾﺎ اﻟﻤﻨﺎﻋﯿﺔ ﻓﻲ ﺳﺮطﺎن اﻟﺜﺪي. وﺑﺎﻟﺘﺎﻟﻲ، ﻗﺪ ﯾﻈﮭﺮEXT1 ﻛﻌﻼﻣﺔ ﺗﻨﺒﺆﯾﺔ ﻣﺴﺘﻘﻠﺔ، وﻋﻼﻣﺔ ﻣﻨﺎﻋﯿﺔ، وھﺪﻓًﺎ ﻋﻼﺟﯿًﺎ ﻣﺴﺘﻘﺒﻠﯿًﺎ ﻷﻧﻮاع ﺳﺮطﺎن اﻟﺜﺪي اﻷﻛﺜﺮ ﻋﺪواﻧﯿﺔ.
530			_aIssues also as CD.
546			_aText in English and abstract in Arabic & English.
650		0	_aBreast cancer
650		0	_aسرطان الثدى
653		0	_aExostosin 1 (EXT1) _aHeparan Sulfate _abreast cancer _aprognosis _aimmune infiltration
700	0		_aSherif Abdelaziz Ibrahim _ethesis advisor.
700	0		_aAhmed Hassan Abd El-Raouf _ethesis advisor.
700	0		_aMahmoud Mohamed Kamel _ethesis advisor.
900			_b01-01-2025 _cSherif Abdelaziz Ibrahim _cAhmed Hassan Abd El-Raouf _cMahmoud Mohamed Kamel _UCairo University _FFaculty of Science _DDepartment of Zoology
905			_aShimaa
942			_2ddc _cTH _e21 _n0
999			_c175637